Thanks to deals signed on Monday alone, another $17 billion is set to change hands in the hyperacquisitive drug business, a single-day record that closes out a bracing quarter for buyouts. But with industry titans paying ever-higher prices for a shrinking number of assets, how long can the good times roll? …read more Source: A […]
The quick-fire pace of biotech IPOs in Paris is set to continue. Inner ear disease specialist Sensorion is the latest to set terms for an IPO that will see it join Cerenis Therapeutics, Ose Pharma and Poxel in a Parisian class of 2015 that has already almost swelled to the size of last year’s crop. […]
Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to an approval in China, according to FiercePharmaAsia. …read more Source: Chi-Med’s fruquintinib meets colorectal cancer PhII primary endpoint
Back in mid-January, CoLucid Pharmaceuticals raised about $37 million to back its Phase III study of a new migraine drug. A week ago the biotech said it had pulled up stakes in Durham, NC, and had temporarily located its HQ in Burlington, MA, as it searched for new offices in Cambridge. And now it has […]
SR One, GlaxoSmithKline’s venture arm, has joined a syndicate backing a big midstage study of a new kidney drug developed by Montreal-based Thrasos Therapeutics. …read more Source: GlaxoSmithKline leads a $21M round for PhII kidney drug developer Thrasos
The small, Houston-based gene therapy company MultiVir has filed for a $70 million IPO with plans to advance its lead program for Ad-p53. …read more Source: Houston-based gene therapy outfit files for $70M IPO
BioDelivery Sciences’ in-development pain gel failed to meet its main goal in a late-stage trial, a surprise turn for the company as it looked forward to an FDA submission. …read more Source: BioDelivery tanks as its pain gel comes up short in Phase III
Durham, NC’s Novan Therapeutics raised $50 million to bankroll a new treatment for acne, persuading the high-profile European investor Malin to buy into the idea. …read more Source: Skincare startup bags $50M to get its acne drug into Phase III
Four months after Pfizer stepped up with a $2.85 billion promise to partner with Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma company has turned around to partner with Intrexon on an upstart CAR-T cancer drug development project. …read more Source: UPDATED: Merck KGaA forges a $941M CAR-T development deal with Intrexon […]
Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential treatments. …read more Source: Novartis tackles immuno-oncology with a $750M Aduro deal for new R&D group
